Last reviewed · How we verify
Paxlovid (Copackaged) — Competitive Intelligence Brief
discontinued
Immunology
Live · refreshed every 30 min
Target snapshot
Paxlovid (Copackaged) (paxlovid) — Pfizer. Paxlovid works by inhibiting the activity of the SARS-CoV-2 protease enzyme, which is essential for the virus's replication.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Paxlovid (Copackaged) TARGET | paxlovid | Pfizer | discontinued | 2023-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Paxlovid (Copackaged) · 11351149 · US
- — Paxlovid (Copackaged) · 11541034 · US
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Paxlovid (Copackaged) CI watch — RSS
- Paxlovid (Copackaged) CI watch — Atom
- Paxlovid (Copackaged) CI watch — JSON
- Paxlovid (Copackaged) alone — RSS
Cite this brief
Drug Landscape (2026). Paxlovid (Copackaged) — Competitive Intelligence Brief. https://druglandscape.com/ci/paxlovid. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab